Lost Money on MoonLake Immunotherapeutics (MLTX)? Urged to Join Class Action Before December 15, 2025 - Contact Levi & Korsinsky

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected shareholders between March 10, 2024, and September 29, 2025 [3]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding their drug candidate SLK, asserting that it would not provide superior clinical benefits compared to BIMZELX, and that its supposed advantages in tissue penetration would not lead to clinical efficacy [4]. - The complaint highlights that the defendants lacked a reasonable basis for their positive statements about SLK's superiority over traditional monoclonal antibodies [4]. Group 2: Investor Information - Shareholders who experienced losses during the specified timeframe are encouraged to seek recovery, regardless of whether they still hold their shares [5]. - Levi & Korsinsky LLP, the firm handling the case, has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [6].